Eterna Therapeutics Inc.

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Its flagship program, IRX-2, is currently undergoing a Phase 2b clinical trial for patients with squamous cell cancer of the head and neck. The company also leverages gene-editing and cell therapy technology to develop treatments for oncology, blood disorders, and monogenic diseases, catering to a diverse range of medical needs.

Products

• IRX-2 therapy for squamous cell cancer

• Gene-editing and cell therapy treatments for oncology, blood disorders, and monogenic diseases